Contact
searchSearch
HMP Global
Videos

Emerging Vitiligo Therapies and Strategies

09/18/2021

In this video, Dr John Harris discusses the emerging therapies for vitiligo.

Dr Harris is the chair of dermatology, founding director of the Vitiligo Clinic and Research Center, and founding director of the Autoimmune Therapeutics Institute at UMass Medical School in Worcester, MA.

Related Content

News
International Panel Defines Generalized Pustular Psoriasis for Clinical and Research Use
04/29/2025
Jessica Garlewicz; Coleen Stern, MA
An international panel of dermatology experts has achieved consensus on a standardized definition and diagnostic criteria for generalized pustular psoriasis (GPP), a rare but serious systemic inflammatory skin disorder.
An international panel of dermatology experts has achieved consensus on a standardized definition and diagnostic criteria for generalized pustular psoriasis (GPP), a rare but serious systemic inflammatory skin disorder.
An international panel of...
04/29/2025
The Dermatologist
Cover Story
Beyond Face Value: Targeted Therapies for Vitiligo and Strategies for Improving Patient Quality of Life
03/06/2025
Iain Noel Encarnacion, MS; Noelle Desir, BA; Susan Taylor, MD
A multidisciplinary approach to care is needed to address the physical and psychological dimensions of this disease.
A multidisciplinary approach to care is needed to address the physical and psychological dimensions of this disease.
A multidisciplinary approach to...
03/06/2025
The Dermatologist
Susan Taylor
Conference Coverage
Advances in Vitiligo Treatment and Management
11/14/2024
Riya Gandhi, MA
At Fall Dermatology Week, Dr Susan Taylor highlighted significant progress in vitiligo treatment, focusing on Janus kinase inhibitors and their potential for repigmentation.
At Fall Dermatology Week, Dr Susan Taylor highlighted significant progress in vitiligo treatment, focusing on Janus kinase inhibitors and their potential for repigmentation.
At Fall Dermatology Week, Dr...
11/14/2024
The Dermatologist
Clinical Insights
The Risk of Keratinocyte Cancer in Patients With Vitiligo
08/05/2024
Riya Gandhi, MA
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
A recent systematic review and...
08/05/2024
The Dermatologist

Recent Highlights

alopecia areata
Conference Coverage
JAK Inhibitors in Alopecia Areata: Long-Term Success, Individualized Strategy, and the Emerging Role of Eyebrow Outcomes
11/26/2025
Jessica Garlewicz
Through patient cases and data review, the presenters emphasized the need to think beyond the scalp, personalize treatment duration and dosing, and recognize the growing significance of eyebrow regrowth as a marker of patient satisfaction.
Through patient cases and data review, the presenters emphasized the need to think beyond the scalp, personalize treatment duration and dosing, and recognize the growing significance of eyebrow regrowth as a marker of patient satisfaction.
Through patient cases and data...
11/26/2025
The Dermatologist
atopic dermatitis
Conference Coverage
Clarifying the Role of IL-13 Inhibitors in Atopic Dermatitis: Clinical Profiles, Comparisons, and Real-World Application
11/26/2025
Jessica Garlewicz
The session emphasized mechanism-driven selection, real-world application, and a comparison of pivotal efficacy data for the 3 IL-13–related biologics currently available: dupilumab, lebrikizumab, and tralokinumab.
The session emphasized mechanism-driven selection, real-world application, and a comparison of pivotal efficacy data for the 3 IL-13–related biologics currently available: dupilumab, lebrikizumab, and tralokinumab.
The session emphasized...
11/26/2025
The Dermatologist
Linda F. Stein Gold, MD
Conference Coverage
Charting a Path to Higher Treatment Targets With JAK Inhibition in Atopic Dermatitis
11/01/2025
Jessica Garlewicz
The session focused on elevating therapeutic expectations in AD care, analyzing data on existing JAK inhibitors, and encouraging dermatologists to challenge treatment inertia.
The session focused on elevating therapeutic expectations in AD care, analyzing data on existing JAK inhibitors, and encouraging dermatologists to challenge treatment inertia.
The session focused on elevating...
11/01/2025
The Dermatologist
Natasha Atanaskova-Mesinkovska, MD, PhD
Conference Coverage
JAK Inhibitors for Alopecia Areata: Clinical Insights and Emerging Strategies
10/28/2025
Jessica Garlewicz
At Fall Clinical 2025, Natasha Atanaskova-Mesinkovska, MD, PhD, presented a candid and case-based review of current treatment strategies for alopecia areata.
At Fall Clinical 2025, Natasha Atanaskova-Mesinkovska, MD, PhD, presented a candid and case-based review of current treatment strategies for alopecia areata.
At Fall Clinical 2025, Natasha...
10/28/2025
The Dermatologist
acne
Conference Coverage
Optimizing Acne Management With Durable Topical and Oral Therapies
10/28/2025
Jessica Garlewicz
At the Fall Clinical 2025 session, Mark Lebwohl, MD, reviewed recent data supporting the long-term efficacy of topical and oral therapies in acne management, focusing on durability, scarring, and sebum reduction.
At the Fall Clinical 2025 session, Mark Lebwohl, MD, reviewed recent data supporting the long-term efficacy of topical and oral therapies in acne management, focusing on durability, scarring, and sebum reduction.
At the Fall Clinical 2025...
10/28/2025
The Dermatologist
April W. Armstrong, MD
Conference Coverage
Rethinking the Role of Orals: Where TYK2 Inhibitors Fit in Psoriasis Management
10/27/2025
Jessica Garlewicz
The discussion centered on patient preferences, mechanism-driven selectivity, and a growing oral therapy pipeline that may shift long-standing practice paradigms.
The discussion centered on patient preferences, mechanism-driven selectivity, and a growing oral therapy pipeline that may shift long-standing practice paradigms.
The discussion centered on...
10/27/2025
The Dermatologist
Mittal Patel-Cohen
Conference Coverage
Hidradenitis Suppurativa: Phenotypes, Pitfalls, and Expanding Treatments
10/26/2025
Riya Gandhi, MA
Dr Patel-Cohen laid out diagnostic pearls, comorbidity considerations, and an expansive update on both conventional and emerging therapies of hidradenitis suppurativa.
Dr Patel-Cohen laid out diagnostic pearls, comorbidity considerations, and an expansive update on both conventional and emerging therapies of hidradenitis suppurativa.
Dr Patel-Cohen laid out...
10/26/2025
The Dermatologist
Brett King
Conference Coverage
Challenges and Treatments in Alopecia Areata
10/26/2025
Riya Gandhi, MA
At Dermatology Week 2025, Brett King, MD, PhD, presented an energizing overview of how far alopecia areata (AA) care has come, and where it is headed.
At Dermatology Week 2025, Brett King, MD, PhD, presented an energizing overview of how far alopecia areata (AA) care has come, and where it is headed.
At Dermatology Week 2025, Brett...
10/26/2025
The Dermatologist
Elizabeth (Lisa) A. Swanson, MD
Conference Coverage
Oral Therapies in Focus: Where Pills Fit in a Biologic-Dominated Psoriasis Landscape
10/24/2025
Jessica Garlewicz
This panel addressed emerging oral IL-23 inhibitors, the durability of current biologics, and patient preferences, framing the discussion around evolving treatment goals like on-treatment remission and real-world clinical needs.
This panel addressed emerging oral IL-23 inhibitors, the durability of current biologics, and patient preferences, framing the discussion around evolving treatment goals like on-treatment remission and real-world clinical needs.
This panel addressed emerging...
10/24/2025
The Dermatologist
psoriasis
Conference Coverage
Integrating GLP-1 Receptor Agonists in Psoriatic Disease: A Dual-Target Approach to Inflammation and Obesity
10/24/2025
Jessica Garlewicz
The discussion centered on the dual role of these agents in reducing systemic inflammation and promoting weight loss—2 factors strongly linked to psoriasis pathophysiology and therapeutic response.
The discussion centered on the dual role of these agents in reducing systemic inflammation and promoting weight loss—2 factors strongly linked to psoriasis pathophysiology and therapeutic response.
The discussion centered on the...
10/24/2025
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use